Latest Content

The acquisition brings together two leaders in mRNA innovation, strengthening BioNTech’s oncology strategy and expanding its R&D and commercialization capabilities.

This episode of Pharma Pulse covers MJH Life Sciences’ acquisition of BPD Healthcare to deepen its reach into hospitals and health systems, investor reaction to Novo Nordisk’s recent board changes, and Mark Cuban’s latest partnership expanding his Cost Plus Drugs platform to disrupt traditional pharmacy pricing models.

In the second part of her Pharma Commerce video interview Megan Wetzel, VP, product, access & affordability at CoverMyMeds, describes how high development costs, personalized treatment models, and an aging population are intensifying the imbalance.

At HLTH 2025, the entrepreneur announced a collaboration between Cost Plus Drugs and President Trump’s TrumpRx platform aimed at improving transparency, reducing drug costs, and reshaping how Americans access their prescriptions.

This episode of Pharma Pulse discusses new data showing a post-Dobbs surge in telehealth medication abortion requests, the FDA’s expedited review of Tzield under its new National Priority Voucher Program, and the launch of a dedicated biopharma air logistics network by Frontier Scientific Solutions and ATSG.

Administrative hurdles and emotional isolation are driving therapy abandonment and worsening outcomes—Megan Wetzel of CoverMyMeds and Jen Butler of Pleio say the solution lies in combining streamlined access with stronger human connection.

The new partnership aims to transform cold chain logistics for life sciences, creating a connected air transport network designed to ensure temperature integrity, regulatory compliance, and faster delivery of critical therapies.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, shares that as DSCSA traceability requirements take full effect, distributors and trading partners are preparing for long-term gains in supply chain security, recall efficiency, and counterfeit prevention.

This episode of Pharma Pulse covers Amazon and WeightWatchers’ partnership to deliver FDA-approved weight-loss medications, Merck’s new biomanufacturing center of excellence in Virginia, and the FDA’s first-ever approval of a TSLP-targeting biologic, Tezspire, for chronic rhinosinusitis with nasal polyps.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, describes how FDA officials are signaling a balanced enforcement approach when it comes to DSCSA enforcement, expecting compliance efforts and documentation, but also recognizing that perfection will take time.

This episode of Pharma Pulse discusses new research linking severe COVID-19 to increased stroke risk among asthma patients, a KFF poll showing divided parental support for vaccine-related agendas, and US News & World Report’s 2026 list of top Medicare Advantage and Part D plan providers.

Aetna, Devoted Health, and UnitedHealth headline the list best Medicare Advantage insurers for next year, while Centene and Humana lead the pack in Part D prescription drug coverage.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, details that after a year of steady progress, manufacturers and distributors report over 97% data accuracy under DSCSA traceability requirements, marking a major milestone in supply chain interoperability and signaling confidence ahead of the November compliance deadline.